Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2025Open Access

Assessing Type 2 Diabetes and GLP-1 agonist response trajectories with a proteogenomic atlas of disease progression

View Full Paper
Ask AI
Bookmark
Share

Authors

STSivateja TangiralaSIShakson IsaacYGYoussef Gehad

Discussion

Loading...

Member takes

Overview

Analysis shows improved prediction of metabolic disease in individuals with type 2 diabetes, suggesting new precision medicine strategies.

Key Points

  • The study found that the Metabolic Atlas of Progression to Diabetes significantly predicts metabolic disease outcomes.
  • Proteomic signatures from MAP-D improved R2 values for BMI and HbA1c prediction in type 2 diabetes beyond demographics alone.
  • Integration with GLP-1 receptor agonist data revealed unique protein signatures associated with therapeutic efficacy.
  • Identify potential therapeutic targets for metabolic disease complications, guiding advanced treatment strategies.

Cite This Study

Tangirala et al. (2025) studied this question.

synapsesocial.com/papers/68da58d8c1728099cfd11009https://doi.org/10.1101/2025.09.26.25336579
View Full Paper
Ask AI
Bookmark
Share